Silver Sponsor Molecular Devices at Society for Laboratory Automation and Screening 2023 International Conference and Exhibition
Showcasing new industry collaborations, automated technology, and workflow innovations that span 3D biology, cell line development, and drug screening
SAN JOSE, Calif., Feb. 22, 2023 – Molecular Devices, LLC., a leading provider of high-performance life science solutions, is demonstrating its latest automated, high-throughput technology at this year’s Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition from February 25 – March 1, 2023, in San Diego, Calif.
“Molecular Devices continues to focus on meeting scientists’ organoid development and screening needs by acquiring a contract development and manufacturer of large-scale patient-derived organoids, and expanding our product portfolio to include automated 3D bioprinter and single-cell dispenser solutions,” said Susan Murphy, President of Molecular Devices. “We look forward to showcasing how our deep expertise, partnerships, and innovative technologies will open the future of next-generation drug discovery.”
Attendees can visit booth #917 to connect with subject matter experts on the company’s latest announcements and advancements in cell line development, 3D biology, and drug screening.
3D biology business acquisition and collaborations
Until recently, organoids have been unsuitable for large-scale drug development due to the laborious nature of growing consistently uniform and robust 3D cell cultures. Through a strategic acquisition and industry collaborations, Molecular Devices is demystifying the process of creating high-volume, viable, and reproducible organoids for drug discovery.
The company recently acquired Cellesce, known for its reliable, assay-ready, patient-derived organoids at scale. When complemented by Molecular Devices’ high-performance, automated hardware and software solutions, the offering is a first-of-its-kind, turnkey solution for organoid development, screening, and analysis.
New collaborations with organoid experts such as HUB Organoids (HUB) and HeartBeat.bio are supporting continued development of next-generation 3D biology technologies that drive step-change reduction in pre-clinical to clinical drug attrition. Molecular Devices is using intestinal organoids from HUB and cardiac organoids from HeartBeat.bio to demonstrate proof of concept for an end-to-end automated workflow that makes 3D biology accessible to the broader scientific community.
Featured automated technologies
Added to the company’s instrument offerings in the last year include an enhanced BAB 400 from Advanced Solutions Life Sciences. Alongside Molecular Devices’ ImageXpress® Cellular Imaging Systems and IN Carta® Image Analysis Software, the automated bioprinting platform aids life scientists in overcoming challenges with reproducing consistent, complex organoid models at scale for drug development.
Joining its line of biopharmaceutical solutions is the award-winning DispenCell™ Single-Cell Dispenser – an automated laboratory instrument designed for fast, easy, and gentle single-cell isolation – from SEED Biosciences Ltd. The technology enables scientists to isolate single-cell lines three times faster and at lower cost compared to existing solutions.
Short Courses, tutorials, podium presentations, and posters
Throughout the show, Molecular Devices and its collaborators will showcase how the company’s life science solutions enable end-to-end automated workflows for advanced scientific discovery.
Level Up Your 3D Cell Culture: From Research to High Throughput* on Sunday, February 26, 2023: *A short course co-led by scientists from Corning Life Sciences and Molecular Devices.
Automating Organoid Models and Assay Workflows on Monday, February 27, 2023: A tutorial delivered by experts from Advanced Solutions Life Sciences and Molecular Devices.
A novel approach for label-free drug efficacy analyses of pancreatic cancer organoids using high-content imaging* on Monday, February 27, 2023*: A podium presentation delivered by SUN Bioscience featuring Molecular Devices technology.
Engineering next generation organoids for biomedical research and drug development* on Monday, February 27, 2023*: A podium presentation delivered by Center for Stem Cell and Organoid Medicine (CuSTOM) at Cincinnati Children’s Hospital Medical Center (CCHMC) featuring Molecular Devices technology.
Leverage automated workflows to enable complex 3D organoid assays on Tuesday, February 28, 2023: Poster by Molecular Devices.
Novel analysis of neural outgrowth in 3D reconstructed human brain micro-tissues with application in compound screening on Tuesday, February 28, 2023: Poster by Molecular Devices.
Automation of Complex Organoid Culture and Assay Workflows on Tuesday, February 28, 2023: Poster by Advanced Solutions Life Sciences featuring Molecular Devices and Cellesce technologies.
A microwell platform to standardize human rectal organoid cultures for high-content imaging and phenotypic analyses on Tuesday, February 28, 2023: SUN Bioscience poster featuring Molecular Devices technology.
For an overview of where to find Molecular Devices at SLAS 2023, visit the company’s webpage here.
About Molecular Devices, LLC.
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.